Development of IGF Signaling Antibody Arrays for the Identification of Hepatocellular Carcinoma Biomarkers

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Zhou, Qi ^a   Mao, Ying Qing ^b   Jiang, Wei Dong ^b   Chen, Yun Ru ^b   Huang, Ren Yu ^b   Zhou, Xiang Bing ^a   Wang, Ya Feng ^a   Shi, Zhi ^b,c   Wang, Zhong Sheng ^b   Huang, Ruo Pan ^b,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b RayBiotech   (United States)

^c South China Biochip Research Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INSULIN; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TUMOR MARKER;

ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; ARTICLE; CANCER TISSUE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MICROARRAY ANALYSIS; OUTCOME ASSESSMENT; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANTIBODIES; ANTIBODIES, IMMOBILIZED; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CLUSTER ANALYSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INSULIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; LIVER NEOPLASMS; MICROARRAY ANALYSIS; PROTEIN ISOFORMS; RECEPTOR, IGF TYPE 1; RECEPTOR, IGF TYPE 2; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SOMATOMEDINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84867410286     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046851     Document Type: Article

References (38)

1. Delafontaine P, Song YH, Li Y, (2004) Expression, regulation, and function of IGF-1, IGF-1R, and IGF-1 binding proteins in blood vessels. Arterioscler Thromb Vasc Biol 24: 435-444.
2. Lelbach A, Muzes G, Feher J, (2005) The insulin-like growth factor system: IGFs, IGF-binding proteins and IGFBP-proteases. Acta Physiol Hung 92: 97-107.
3. Chao W, D'Amore PA, (2008) IGF2: epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 19: 111-120.
4. Clemmons DR, (2007) Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov 6: 821-833.
5. Elmlinger MW, Deininger MH, Schuett BS, Meyermann R, Duffner F, et al. (2001) In vivo expression of insulin-like growth factor-binding protein-2 in human gliomas increases with the tumor grade. Endocrinology 142: 1652-1658.
6. Muller HL, Oh Y, Lehrnbecher T, Blum WF, Rosenfeld RG, (1994) Insulin-like growth factor-binding protein-2 concentrations in cerebrospinal fluid and serum of children with malignant solid tumors or acute leukemia. J Clin Endocrinol Metab 79: 428-434.
7. Collett-Solberg PF, Cohen P, (2000) Genetics, chemistry, and function of the IGF/IGFBP system. Endocrine 12: 121-136.
8. Ricort JM, (2004) Insulin-like growth factor binding protein (IGFBP) signalling. Growth Horm IGF Res 14: 277-286.
9. Annunziata M, Granata R, Ghigo E, (2011) The IGF system. Acta Diabetol 2011 Mar;48 (1) (): 1-9.
10. Chaves J, Saif MW, (2011) IGF system in cancer: from bench to clinic. Anticancer Drugs 22 (3) (): 206-12.
11. Rosenzweig SA, Atreya HS, (2010) Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol 80 (8) (): 1115-24.
12. Tognon CE, Sorensen PH, (2012) Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 16 (1) (): 33-48.
13. Ruan W, Lai M, (2010) Insulin-like growth factor binding protein: a possible marker for the metabolic syndrome? Acta Diabetol 47 (1) (): 5-14.
14. Huang RP, (2004) Cytokine protein arrays. Methods Mol Biol 264: 215-231.
15. Huang RP, (2003) Cytokine antibody arrays: a promising tool to identify molecular targets for drug discovery. Comb Chem High Throughput Screen 6: 769-775.
16. Huang RP, (2003) Protein arrays, an excellent tool in biomedical research. Front Biosci 8: d559-576.
17. Huang RP, (2001) Simultaneous detection of multiple proteins with an array-based enzyme-linked immunosorbent assay (ELISA) and enhanced chemiluminescence (ECL). Clin Chem Lab Med 39: 209-214.
18. Engvall E, (1977) Quantitative enzyme immunoassay (ELISA) in microbiology. Med Biol 55: 193-200.
19. Reen DJ, (1994) Enzyme-linked immunosorbent assay (ELISA). Methods Mol Biol 32: 461-466.
20. Leng SX, McElhaney JE, Walston JD, Xie D, Fedarko NS, et al. (2008) ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J Gerontol A Biol Sci Med Sci 63: 879-884.
21. Iakova P, Timchenko L, Timchenko NA, (2011) Intracellular signaling and hepatocellular carcinoma. Semin Cancer Biol 21: 28-34.
22. El-Serag HB, (2011) Hepatocellular carcinoma. N Engl J Med 365: 1118-1127.
23. Wu J, Zhu AX, (2011) Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol 4: 30.
24. Su TS, Liu WY, Han SH, Jansen M, Yang-Fen TL, et al. (1989) Transcripts of the insulin-like growth factors I and II in human hepatoma. Cancer Res 49: 1773-1777.
25. Scharf JG, Schmidt-Sandte W, Pahernik SA, Ramadori G, Braulke T, et al. (1998) Characterization of the insulin-like growth factor axis in a human hepatoma cell line (PLC). Carcinogenesis 19: 2121-2128.
26. Yang DY, Rogler CE, (1991) Analysis of insulin-like growth factor II (IGF-II) expression in neoplastic nodules and hepatocellular carcinomas of woodchucks utilizing in situ hybridization and immunocytochemistry. Carcinogenesis 12: 1893-1901.
27. Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, et al. (1988) Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 48: 6844-6849.
28. Ng IO, Lee JM, Srivastava G, Ng M, (1998) Expression of insulin-like growth factor II mRNA in hepatocellular carcinoma. J Gastroenterol Hepatol 13: 152-157.
29. Uchida K, Kondo M, Takeda S, Osada H, Takahashi T, et al. (1997) Altered transcriptional regulation of the insulin-like growth factor 2 gene in human hepatocellular carcinoma. Mol Carcinog 18: 193-198.
30. Boissan M, Beurel E, Wendum D, Rey C, Lecluse Y, et al. (2005) Overexpression of insulin receptor substrate-2 in human and murine hepatocellular carcinoma. Am J Pathol 167: 869-877.
31. Gong Y, Cui L, Minuk GY, (2000) The expression of insulin-like growth factor binding proteins in human hepatocellular carcinoma. Mol Cell Biochem 207: 101-104.
32. Ranke MB, Maier KP, Schweizer R, Stadler B, Schleicher S, et al. (2003) Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res 60: 174-180.
33. Pavelic K, Bukovic D, Pavelic J, (2002) The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med 8: 771-780.
34. Osipo C, Dorman S, Frankfater A, (2001) Loss of insulin-like growth factor II receptor expression promotes growth in cancer by increasing intracellular signaling from both IGF-I and insulin receptors. Exp Cell Res 264: 388-396.
35. Sztefko K, Hodorowicz-Zaniewska D, Popiela T, Richter P, (2009) IGF-I, IGF-II, IGFBP2, IGFBP3 and acid-labile subunit (ALS) in colorectal cancer patients before surgery and during one year follow up in relation to age. Adv Med Sci 54: 51-58.
36. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, et al. (2005) Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 58: 361-366.
37. Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, et al. (2001) Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or promoter? Cancer Res 61: 8601-8610.
38. Lin Y, Huang R, Chen LP, Lisoukov H, Lu ZH, Li SY, et al. (2003) Profiling of cytokine expression by biotin-labeled-based protein arrays. Proteomics 3: 1750-1757.